LGND Financial Facts
Discontinued operations: 0Net income (loss): -0.2
See Full Income Statement
Current portion of lease termination payments: 0
Commitments and contingencies: 0
See Full Balance Sheet
Ligand Pharmaceuticals Inc. (LGND) Earnings
|
Expand Research on LGND
| Next EPS Date | N/A | EPS Growth Rate | N/A |
|---|---|---|---|
| Average EPS % Beat Rate | +30.0% | Revenue Growth Rate | N/A |
| Average % Move 1-Wk after EPS | -7.0% | Normal Earnings Time | After Close |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 8/8/22 | Q222 | N/A | $0.50 | N/A | N/A | $37.01M | N/A | N/A | N/A | ||
| 5/4/22 |  |
Q122 | $0.76 | $0.66 | +$0.10 | $45.7M | $34.21M | N/A |  | | Details |
| 2/17/22 | |
Q421 | $1.80 | $1.37 | +$0.43 | $72.5M | $65.32M | N/A | | | Details |
| 11/9/21 | |
Q321 | $1.58 | $1.04 | +$0.54 | $64.8M | $55.65M | N/A | | | Details |
| 7/29/21 | |
Q221 | $1.63 | $1.34 | +$0.29 | $54.7M | $70.41M | N/A | | | Details |
| 5/3/21 | |
Q121 | $1.41 | $1.12 | +$0.29 | $55.2M | $62.85M | N/A | | | Details |
| 2/3/21 | |
Q420 | $1.62 | $0.99 | +$0.63 | $70M | $54.24M | N/A | | | Details |
| 10/30/20 | |
Q320 | $1.04 | $0.98 | +$0.06 | $41.8M | $44.36M | N/A | | | Details |
